Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 24, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

Pelvic lymph node dissection in prostate cancer.

Alberto Briganti1, Michael L Blute, James H Eastham

  • 1Department of Urology, Vita-Salute University, Milan, Italy. briganti_alberto@yahoo.it

European Urology
|March 20, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study.

Urologic oncology·2017
Same author

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer.

Urology case reports·2017
Same author

Diagnostic Accuracy of <sup>64</sup>Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.

Urology·2017
Same author

The Microbiome of the Prostate Tumor Microenvironment.

European urology·2017
Same author

Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study.

Urologic oncology·2017
Same author

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer.

Clinical genitourinary cancer·2017

Pelvic lymph node dissection (PLND) improves prostate cancer staging accuracy, especially when extended. However, extended PLND may be safely omitted in low-risk prostate cancer patients, though its oncologic safety is unproven.

Area of Science:

  • Urology
  • Oncology
  • Surgical Pathology

Background:

  • Pelvic lymph node dissection (PLND) is crucial for detecting lymph node metastases in prostate cancer (PCa).
  • The therapeutic benefit and optimal extent of PLND in PCa management remain subjects of ongoing debate.
  • Current staging tools for PLND need assessment regarding their applicability and accuracy.

Purpose of the Study:

  • To systematically review the literature on the role and extent of PLND in PCa staging and outcomes.
  • To evaluate existing recommendations and staging tools for determining the need for PLND.
  • To analyze the long-term outcomes of node-positive PCa patients based on the extent of nodal invasion.

Main Methods:

  • A comprehensive Medline search was conducted for original articles, reviews, and editorials on PLND in PCa.

Related Experiment Videos

Last Updated: Jun 24, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

  • Keywords included prostate cancer, pelvic lymph node dissection, radical prostatectomy, imaging, and complications.
  • Data from selected studies focusing on PLND's role in staging and outcomes were reviewed and discussed.

    • Main Results:

    • PLND remains the most accurate method for detecting lymph node invasion (LNI) in PCa, surpassing imaging techniques.
    • Extended PLND (ePLND) significantly improves metastasis detection compared to limited PLND (lPLND), which has poor staging accuracy.
    • While nomograms exist to guide PLND, they are based on older data; ePLND may be omitted in low-risk PCa (<8% LNI) but oncologic safety is unknown. Patients with low-volume nodal metastases have good survival rates.

    Conclusions:

    • If PLND is indicated for prostate cancer, it should be an extended procedure (ePLND).
    • Staging ePLND can potentially be omitted in low-risk PCa patients due to low LNI rates, but oncologic safety requires further investigation.
    • Patients with low-volume nodal metastases demonstrate favorable long-term prognoses, although the direct impact of PLND on these outcomes needs further determination.